Merck Zilovertamab Shows 100% Remission in DLBCL Trial
Merck announced positive Phase 2 trial data for zilovertamab vedotin, an investigational antibody-drug conjugate targeting ROR1, in combination with...
Orca Bio Shows Promising 3-Year Survival in Hematological Malignancies
Orca Bio presented positive three-year follow-up data for its allogeneic T-cell immunotherapy, Orca-T, at the 66th American Society of...
Vertex Pharma Casgevy Exagamglogene Autotemcel: Positive Long-Term Data
Vertex Pharmaceuticals announced long-term data from global clinical trials of CASGEVY, a CRISPR/Cas9 gene-edited therapy, for severe sickle cellsickle...
Kite Pharma Yescarta Curative Potential in Relapsed Lymphoma
Kite, a Gilead Company, presented three analyses of Yescarta (axicabtagene ciloleucel) at the 66th American Society of Hematology (ASH)...
Bluebird Bio Lyfgenia Gene Therapy Shows Positive Long-Term Sickle Cell Disease Data
Bluebird bio announced updated data from its LYFGENIA gene therapy for sickle cellsickle cell disease (SCD) patients with a...
Innate Pharma & IFLI Announce $7.9M Investment for IPH6501 in Follicular Lymphoma
Innate Pharma and the Institute for Follicular Lymphoma (IFLI) have partnered to explore the potential of IPH6501, Innate’s anti-CD20...
Exploring the Future of Membrane Protein Modulation in Clinical Trials with Rectify Pharmaceuticals
In this interview, we speak with Rajesh Devraj, Ph.D., President & CEO and Pol Boudes, M.D., Chief Medical Officer...
Datopotamab Deruxtecan Shows Promising Activity in EGFR-Mutated NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate, showed promising results in a pooled analysis of two clinical trials...
Mirailab Launches NMN Supplements and Cosmetics in UAE
MIRAILAB BIOSCIENCE Inc. has launched its β-Nicotinamide Mononucleotide (β-NMN) supplement brand, “MIRAI LAB,” in the UAE. NMN, found naturally...
Veracyte Decipher Prostate Test Recommended in NCCN Guidelines
Veracyte’s Decipher Prostate Genomic Classifier is the only gene expression test included in the 2025 National Comprehensive Cancer Network...